Atogepant: First Approval

被引：36

作者：

Deeks, Emma D. ^{[1
]}

机构：

[1] Springer Nat, Private Bag 65901, Auckland 0754, New Zealand

来源：

DRUGS | 2022年 / 82卷 / 01期

关键词：

PREVENTIVE TREATMENT; MIGRAINE; SAFETY;

D O I：

10.1007/s40265-021-01644-5

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Atogepant (Qulipta (TM)) is an orally administered, small-molecule, calcitonin gene-related peptide (CGRP) receptor antagonist being developed by AbbVie for the prophylaxis of migraine. In September 2021, atogepant was approved in the USA for the preventive treatment of episodic migraine in adults. The drug is also in phase 3 clinical development for the preventive treatment of migraine in various other countries. This article summarizes the milestones in the development of atogepant leading to this first approval for the preventive treatment of episodic migraine in adults.

引用

页码：65 / 70

页数：6

共 23 条

[1]

AbbVie, 2021, FDA APPR QULIPTA AT

[2]

AbbVie, QULIPTA AT TABL OR U, P2021

[3] Atogepant for the Preventive Treatment of Migraine [J].

Ailani, Jessica ;

Lipton, Richard B. ;

Goadsby, Peter J. ;

Guo, Hua ;

Miceli, Rosa ;

Severt, Lawrence ;

Finnegan, Michelle ;

Trugman, Joel M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (08) :695-706

[4]

Allergan and Merck Co, 2015, ALL ENT LIC AGR MERC

[5] Atogepant Has No Clinically Relevant Effects on the Pharmacokinetics of an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Participants [J].

Ankrom, Wendy ;

Xu, Jialin ;

Vallee, Marie-Helene ;

Dockendorf, Marissa F. ;

Armas, Danielle ;

Boinpally, Ramesh ;

Min, K. Chris .

JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 (09) :1157-1165

[6]

Ashina M, HEADACHE, V2021, P61

[7]

Ashina M, 2021, NEUROLOGY, V96

[8]

Boinpally R, 2021, HEADACHE, V61, P94

[9]

Boinpally R, 2020, HEADACHE, V60, P35

[10]

Boinpally R, NEUROLOGY, V96

← 1 2 3 →